Pharus SICAV - Medical Innovation Class B EUR Acc

The objective of this Sub-Fund is to achieve growth by investing in equities or similar securities issued by biopharmaceutical companies that are at the forefront of innovation in the medical sector. The Sub-Fund will invest at least two-thirds of its total assets in equities issued by companies operating in this sector, with a focus on North America and Western Europe.

To achieve its objective, this Sub-Fund holds a diversified portfolio composed of securities issued by listed companies, including ordinary or preference shares, bonds, and up to 10% of the Sub-Fund’s net assets in UCITS and/or other UCIs. The majority of investments are focused on biopharmaceutical companies in North America and Western Europe.

The risks associated with this Sub-Fund include counterparty risk, currency risk, derivative risk, liquidity risk, and operational risk. These risks may impact the value of the Fund’s investments or expose the Fund to losses. The Fund is rated in risk category 7 due to the nature of its investments into equity securities. Additional risk factors are described in the prospectus of the Fund.

https://www.pharusmanagement.com/lu/en/sicav-funds/LU1491986011